PlanMySupps

Cover Block

Attribute	Details
Company	PlanMySupps
Tagline	Evidence-based decision system for precision supplementation. [PlanMySupps, retrieved 2024]
Headquarters	Paris, France
Founded	2025
Stage	Pre-Seed
Business Model	Direct-to-Consumer (DTC), B2B2C
Industry	Healthtech
Technology	Software (Non-AI)
Geography	Global / Remote-First
Growth Profile	Venture Scale
Founding Team	Solo founder
Funding Label	Pre-Seed

Links

• Website: https://planmysupps.com/
• LinkedIn: https://www.linkedin.com/in/cristinagall/

PlanMySupps maintains a minimal public footprint. The company website is the primary source for product information, while the LinkedIn profile of founder Cristina Gall provides the most detailed public view of the founding team and the company's positioning.

PlanMySupps is a Paris-based healthtech startup building software to generate personalized supplement protocols, a proposition that stands out for its explicit grounding in clinical evidence rather than wellness marketing. Founded in 2025 by Cristina Gall, the company positions its product as an evidence-based decision system for precision supplementation [PlanMySupps, retrieved 2024]. The founder's background in nutritional epidemiology provides a credible foundation for the product's scientific positioning [LinkedIn, retrieved 2024]. As of late 2026, the company has paying clients and revenue from its concierge service, with client acquisition entirely through organic referral [Author note, Sep 2026]. The next 12 to 18 months will be critical for demonstrating whether the evidence-based protocol engine can secure additional paying customers and forge the data partnerships necessary to validate its technical claims.

Data Accuracy: YELLOW -- Core product claims from company site; team backgrounds from professional profiles; absence of funding corroborated by search. Founder-provided corrections applied Sep 2026.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Direct-to-Consumer (DTC), B2B2C
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Global / Remote-First
Growth Profile	Venture Scale
Founding Team	Solo founder

How the Company Got Here

PlanMySupps was founded in 2025 in Paris, France, as a remote-first healthtech venture [Crunchbase, 2026]. The company’s public identity is anchored by its founder, Cristina Gall, who has structured the business around both a direct-to-consumer software model and B2B2C partnerships [PlanMySupps, 2024] [Author note, Sep 2026].

The company’s primary public milestone remains the launch of its website and product concept, which describes a protocol-generation engine for personalized supplement plans [PlanMySupps, 2024]. PlanMySupps has paying clients and revenue from its concierge service, where the founder delivers protocols directly while the automated decision system is being built [Author note, Sep 2026]. There is no public record of institutional funding rounds or major partnership disclosures as of 2024-2025 [Perplexity Sonar Pro Brief, retrieved 2024].

The founder’s academic and professional backgrounds provide the core narrative for the company’s evidence-based positioning. Cristina Gall holds an MSc in Nutritional Epidemiology from Harvard School of Public Health, a credential directly cited in the product’s framing [LinkedIn, 2024]. Her prior experience includes investment banking at J.P. Morgan, health policy at the European Commission, and health-tech operations as Head of Customer Success at Shleep [Author note, Sep 2026].

Data Accuracy: YELLOW -- Company founding details are confirmed via Crunchbase and founder profiles; operational milestones and entity structure are not publicly documented. Founder-provided corrections applied Sep 2026.

Product and Technology

The product is an evidence-based decision system for precision supplementation. It is a system that turns blood biomarkers, health goals, and personal context into supplement protocols specifying form, dose, and timing [Author note, Sep 2026]. PlanMySupps is brand-neutral: it does not sell supplements and has no affiliate programs. The recommendation logic is rules-based, not generative AI, and includes per-marker safety gates that refer users to a physician when results warrant it [Author note, Sep 2026].

Its differentiation hinges on the application of nutritional epidemiology to filter recommendations. The company's public positioning repeatedly emphasizes an evidence-based methodology, a claim anchored by founder Cristina Gall's academic background in nutritional epidemiology from Harvard [LinkedIn, retrieved 2024]. The product appears to generate individualized regimens by taking user inputs and structuring them against a database of clinical evidence, though the specific algorithms, data sources, and validation processes are not documented on the public site [Perplexity Sonar Pro Brief, retrieved 2024].

PlanMySupps operates two co-equal channels: direct-to-consumer, and B2B2C through laboratory partnerships. This includes a partnership with a laboratory in Doha, Qatar [Author note, Sep 2026]. The website is pitched to individuals seeking a scientifically-grounded supplement plan. The technical stack is not publicly disclosed, and there is no mention of regulatory clearances in available materials.

Data Accuracy: YELLOW -- Product claims are sourced from the company website; technical and operational details are not independently verified. Founder-provided corrections applied Sep 2026.

Where the Demand Sits

The market for personalized health interventions, particularly in supplements, is expanding as consumers increasingly seek data-driven alternatives to generic over-the-counter products. Demand is anchored in a growing body of research linking specific micronutrients to health outcomes, which has elevated consumer expectations. The public-facing narrative from PlanMySupps and its competitors emphasizes "evidence-based" recommendations, a direct response to consumer skepticism towards the unsubstantiated claims common in the broader wellness industry [PlanMySupps, retrieved 2024]. The Middle East-North Africa region is one of the fastest-growing wellness markets globally, with a large share of PlanMySupps's concierge clients based in Qatar [Global Wellness Institute, 2025] [Author note, Sep 2026].

Adjacent and substitute markets are significant. The most direct substitute is the traditional retail supplement aisle, a massive but undifferentiated market. More sophisticated adjacent markets include telehealth platforms that integrate supplement recommendations into broader care plans, and functional medicine practices that offer highly personalized protocols but at a much higher cost and with direct clinician involvement. The company's positioning as "infrastructure" suggests a potential bridge between these clinical services and the mass market.

Regulatory and macro forces present both a barrier and a potential moat. In the United States and Europe, dietary supplements are largely regulated under food safety frameworks rather than pharmaceutical pre-approval processes. This allows for faster product iteration but creates a trust deficit, as consumers cannot rely on regulatory vetting for efficacy. A company building a reputation on clinical evidence could differentiate itself, but it also assumes the liability of interpreting complex scientific literature for a general audience.

Data Accuracy: YELLOW -- Market sizing and driver analysis is inferred from adjacent company positioning and industry commentary; no third-party market report specific to PlanMySupps's model is publicly cited. Founder-provided corrections applied Sep 2026.

Competitive Landscape

PlanMySupps enters a market where established players have built consumer trust through brand recognition and direct product fulfillment, positioning itself as a software layer that prioritizes evidence-based protocol generation over supplement sales.

Company	Positioning	Stage / Funding	Notable Differentiator
PlanMySupps	Software for personalized, evidence-based supplement protocol generation.	Pre-Seed; no public funding rounds.	Focus on nutritional epidemiology and a protocol-generation engine, not direct e-commerce.
Rootine	Direct-to-consumer personalized vitamins based on blood test data.	Venture-backed; $10M Series A in 2021.	Uses at-home blood testing to tailor micronutrient formulas.
Persona / Care/of	DTC personalized vitamin subscription services.	Persona acquired by Nestlé; Care/of raised $29M.	Strong brand recognition and scaled subscription models.
Hormonify	Platform focused on hormone-balancing supplement protocols.	Early-stage; specific funding not public.	Niche focus on hormonal health for a specific demographic.

Competition in the personalized supplement space is segmented by the depth of personalization and the underlying business model. PlanMySupps sits apart by not selling physical products, instead offering the decision-making infrastructure. This places it adjacent to coaching platforms and clinical tools used by practitioners, a segment where it currently has a B2B2C partnership in Doha, Qatar [Author note, Sep 2026].

The company's stated edge is its foundational emphasis on nutritional epidemiology and clinical evidence, as articulated by founder Cristina Gall's academic background [LinkedIn, retrieved 2024]. This positions the protocol engine as a filter against the noise of the unregulated supplement market. This edge is perishable, however, as it relies on the perceived authority of its methodology rather than patented technology or exclusive data partnerships.

Data Accuracy: YELLOW -- Competitor profiles and funding stages are confirmed via public databases and company sites; PlanMySupps' differentiation is sourced from its own materials without third-party validation. Founder-provided corrections applied Sep 2026.

Opportunity

If PlanMySupps can successfully productize its evidence-based protocol engine, the opportunity lies in becoming the trusted decision layer for a global supplements market that has long operated on anecdote and marketing. The headline opportunity is the creation of a category-defining platform for supplement personalization, one that could shift consumer and practitioner behavior away from generic recommendations. The company's positioning as "infrastructure" for protocols, rather than a simple e-commerce brand, suggests a wedge into becoming the default software for generating and managing supplement regimens [PlanMySupps, retrieved 2024].

Scenario	What happens	Catalyst	Why it's plausible
B2B White-Label Engine	The protocol-generation software is licensed to telehealth platforms, functional medicine clinics, and wellness brands.	A partnership with a major practitioner-focused supplement distributor (e.g., Fullscript) or a digital health platform seeking to add supplement personalization.	The market already shows demand for using lab data to guide supplement plans, and established platforms seek to add personalized services [Fullscript, retrieved 2026].
Consumer Subscription Scale	The direct-to-consumer app becomes a must-have for health-optimizing individuals, scaling to millions of users.	The launch of a mobile app that simplifies protocol adherence and tracking, coupled with content marketing that establishes category authority.	Consumer demand for personalized, science-backed health guidance is a durable trend; successful DTC health apps demonstrate the model [Crunchbase, retrieved 2026].
Regulatory & Standard-Setting	The company's evidence-based methodology becomes a de facto standard, leading to B2G contracts or mandatory use in certain care pathways.	Publication of peer-reviewed research validating the protocol engine's outcomes, attracting institutional and governmental interest.	Public health entities are increasingly focused on evidence-based approaches to nutrition and supplementation; a Harvard-linked, research-grounded methodology could attract such partnerships [Medgevity Health, retrieved 2026].

Data Accuracy: ORANGE -- Opportunity analysis is based on company positioning and market dynamics; specific growth catalysts and comparables are inferred from adjacent market evidence.

Sources

1. [PlanMySupps, retrieved 2024] Personalized, Evidence-Based Supplement Plans | https://planmysupps.com/
2. [LinkedIn, retrieved 2024] Cristina Gall's LinkedIn Profile | https://www.linkedin.com/in/cristinagall/
3. [RocketReach, retrieved 2024] Cristina Gall's RocketReach Profile | https://rocketreach.co/cristina-gall_b511394348572533
4. [Crunchbase, 2026] List of top Paris Startups Founded in 2021 | https://www.crunchbase.com/hub/paris-startups-founded-in-2021
5. [Supplement Coaching, retrieved 2026] About Cristina Gall, Harvard-Trained Supplement Coach | https://www.supplementcoaching.com/about-cristina
6. [Hormonify, retrieved 2026] Benefits of a Personalized Supplement Protocol | https://hormonify.com/benefits-of-a-personalized-supplement-protocol/
7. [Fullscript, retrieved 2026] Using Lab Data to Guide Personalized Supplement Plans | https://fullscript.com/blog/steps-to-personalize-supplement-recommendations
8. [Medgevity Health, retrieved 2026] Personalized Supplement Strategies | https://www.medgevityhealth.com/home-pages/personalized-supplement-strategies
9. [Crunchbase, 2021] Rootine Funding Round | https://www.crunchbase.com/
10. [Crunchbase, 2019] Persona / Care/of Funding | https://www.crunchbase.com/
11. [Crunchbase, retrieved 2026] Consumer Health App Market | https://www.crunchbase.com/
12. [Global Wellness Institute, 2025] The Global Wellness Economy: 2025 Trends and Forecasts | https://globalwellnessinstitute.org/press-room/press-releases/2025-global-wellness-economy-report/